OxStem Ltd. was co-founded by the leading British scientists and chemists Professors Dame Kay Davies, Stephen G. Davies and Angela J. Russell. OxStem has developed cell programming therapies that could treat a range of usually age-related conditions – dementia, heart failure, macular degeneration, diabetes and cancer. The company has already established four subsidiaries each with a specific disease focus: OxStem Oncology, OxStem Neuro and OxStem Ocular and OxStem Cardio. With the new technology, it is possible to identify new types of drugs that can re-program or stimulate existing endogenous cells, replacing previously deceased or dormant cellular processes. The novelty contains in the unique combination of know-how in large-scale stem cell culture. This enables phenotypic screening and preclinical models, together with proven medicinal chemistry expertise. OxStem aims to expand a collection of drug candidates and reactivate these innate repair processes as a therapeutic paradigm applicable to a wide range of degenerative diseases.
The rare disease therapy was developed by Modis Therapeutics. This company is based on Columbia University research. Modis Therapeutics was formed through a collaboration with academic experts in mitochondrial biology to develop disease-modifying therapies for rare genetic diseases. The company completed a series A financing with investments from F-Prime Capital Partners, OrbiMed, Aceras Life Sciences, and Osage University Partners. The company has assembled a management team with deep experience in the development of high-impact products for serious diseases at leading biotech and pharmaceutical companies. Modis is a dedicated team, passionate about bringing novel therapies to patients with uncommon diseases.
The 'smart' bandage that tracks the healing of the wound beneath it monitors the level of activity of the patient and, if necessary, sends the data back to the doctor, was developed by scientists from Swansea University's Institute of Life Science.
Exclusive interview for SPINOFF.COM with Dr. Luka Fajs, Eclipse Diagnostics Inc., CEO, about blood-testing medical platform
Eclipse Diagnostics is a biotech company developing a patented device for early stroke (lat. Apoplexia) detection. Strokes are the second cause of death in the US and this device can help 7M stroke patients prevent another stroke. Eclipse Diagnostics are raising capital for the FDA approval process.
The core of stroke home test is a patented testing platform - ELLI - that enables measurement of the levels of disease biomarkers within 15 minutes using only a drop of blood and a single-step procedure. The principle of the technology (that has been peer-reviewed in international journals) is a combination of the underlying technologies of the two most successful tests in the market: pregnancy-test technology and the glucose-test technology, that are merged together with a patented chemical formulation that enables laboratory-grade measurement accuracy at a low cost. The technology originates from Prof. Robert S. Marks's laboratory in the Ben-Gurion University (BGUni) of the Negev and Nanyang Technological University Singapore. The resulting technology enables a rapid and easy-to-use test for detection of stroke biomarkers, infectious disease, and other medical or non-medical conditions.
Automating laboratory workflows hasn't been convenient before. The spinoff of Department of Biosystems Science and Engineering at ETH Zurich, UniteLabs AG is building new kind of flexible, easy and affordable automation for life science research facilities. The novel technology allows access to automation software remotely, schedule the scientific work and geta real-time updates. UniteLabs uses computer vision to localise and track laboratory instruments. By combining the latest robotic technologies, computer vision tools, and experience from both manual and automated labs into a software solution, it enables lab automation with previously unseen ease and flexibility. This allows ad-hoc automation for temporary experiments and low-cost alternative to today's custom made automation systems.
A Virginia Tech research team has developed a battery that runs on sugar and has an unmatched energy density, a development that could replace conventional batteries with ones that are cheaper, refillable, and biodegradable. Y.H. Percival Zhang, an associate professor of biological systems engineering in the College of Agriculture and Life Sciences and the College of Engineering, created battery, which has an energy density an order of magnitude higher than others, allowing it to run longer before needing to be refueled. In as soon as three years, Percival Zhang’s new battery could be running some of the cell phones, tablets, video games, and the myriad other electronic gadgets that require power in energy-hungry world.